BIO Bio-Rad Laboratories, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
BIO Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Devices
Current Price
Live
$296.57
Analyst Target
$348.0
+17.3%
Upside
52W High
$373.69
52W Low
$211.43
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
Bio-Rad Laboratories has a Piotroski F-Score of 6/9, indicating stable financial health, but lacks an Altman Z-Score for distress risk assessment. The company shows strong gross margins and solid earnings surprises historically, yet faces near-term headwinds with negative profit margins, declining EPS Q/Q, and weak revenue growth. Valuation metrics suggest premium pricing with a Forward P/E of 29.22 and Price/Sales of 3.13, while insider activity is bearish and analyst recommendation remains 'buy' with a $348 target. Despite solid balance sheet strength, profitability deterioration and lack of dividend or intrinsic value clarity limit upside conviction.
Key Strengths
Piotroski F-Score of 6 indicates stable financial health with no immediate distress signals
Exceptionally strong liquidity position with Current Ratio of 5.44 and Quick Ratio of 3.62
High gross margin of 52.36% reflects pricing power and efficient cost control in core operations
Consistent history of beating earnings estimates, with 3 out of last 4 quarters above expectations and average surprise of 36.31%
Low Debt/Equity ratio of 0.21 suggests conservative capital structure and low leverage risk
Key Risks
Negative profit margin of -26.43% and negative ROE of -9.50% indicate current unprofitability and poor return on equity
Revenue growth of only 0.50% YoY signals stagnation in top-line expansion
Most recent Q/Q EPS growth declined by 13.4%, showing near-term earnings deterioration
Insider selling activity (1 sale, $0.21M) over past 6 months reflects lack of confidence from management
Lack of Graham Number and Intrinsic Value data prevents reliable fair value estimation, increasing valuation uncertainty
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare BIO against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning BIO from our newsroom.
Newest → oldest
No matching news yet.